Endo Paget Bisphosphonate Chf

---
name: endo-paget-bisphosphonate-chf
description: This skill suggests treatment with a bisphosphonate in patients with Paget's disease who also have symptomatic congestive heart failure. Triggers include the presence of Paget's disease alongside signs or symptoms of congestive heart failure such as dyspnea, orthopnea, or elevated jugular venous pressure.
---

# Treat with bisphosphonate in Paget's disease with congestive heart failure

## STEP 1 — Gather Information
Confirm Paget's disease diagnosis via clinical features, plain radiographs, radionuclide bone scan, and elevated bone turnover markers (total ALP or P1NP/BSAP/CTx). Assess for congestive heart failure: symptoms (dyspnea, orthopnea, PND), signs (elevated JVP, peripheral edema, S3 gallop), BNP/NT-proBNP, echocardiogram for high-output state, and basic labs (renal function, calcium, vitamin D). Review contraindications to bisphosphonate (eGFR <35 mL/min, untreated hypocalcemia, pregnancy).

## STEP 2 — Rule In / Rule Out
Rule in if both active Paget's disease (elevated bone turnover marker or radiographic/scan evidence) **and** symptomatic congestive heart failure are present. Rule out if either condition is absent or if a contraindication to bisphosphonate exists (severe renal impairment, uncorrected hypocalcemia).

## STEP 3 — Classify or Stratify
Stratify by CHF severity (NYHA class I‑IV) and Paget's disease extent (monostotic vs polyostotic). For NYHA class II‑IV or polyostotic disease, prefer potent IV bisphosphonate; for NYHA I with monostotic disease and no contraindication, oral bisphosphonate may be considered.

## STEP 4 — Decide
If no contraindication, administer a single 5 mg IV zoledronate infusion over 15 minutes (pre‑hydrate, ensure vitamin D sufficiency, correct calcium). If zoledronate contraindicated, use an oral bisphosphonate (e.g., alendronate 40 mg daily for 6 months). Reassess bone turnover markers and cardiac symptoms at 3‑6 months.

## Clinical Guardrails / Mimics / Pitfalls
Do not give bisphosphonate in severe renal impairment (eGFR <35) without dose adjustment; avoid in untreated vitamin D deficiency or hypocalcemia due to risk of symptomatic hypocalcemia post‑infusion. Do not rely solely on symptoms to assess CHF response; use objective markers (BNP, echocardiogram). Avoid in pregnancy or breastfeeding. Monitor for acute phase reaction (fever, myalgias) and treat with acetaminophen/NSAIDs prophylactically.

## Concrete Clinical Example
A 70‑year‑old woman with known polyostotic Paget's disease (ALP 280 U/L, bone scan showing widespread uptake) presents with progressive dyspnea on exertion, orthopnea, BNP 620 pg/mL, and echocardiogram showing high‑output heart failure. Her eGFR is 55 mL/min, vitamin D 32 ng/mL, calcium normal. After confirming no contraindication, she receives zoledronate 5 mg IV. At 4 months, ALP falls to 110 U/L, BNP decreases to 210 pg/mL, and dyspnea improves.

**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2910